Response to: A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants

doi:10.1016/j.vaccine.2019.04.003

Comment

. 2019 May 21;37(23):2990.

doi: 10.1016/j.vaccine.2019.04.003.

Response to: A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants

P Gillard¹, B Benninghoff²

Affiliations

¹ GlaxoSmithKline, Avenue Fleming, 20, Wavre B1300, Belgium. Electronic address: Paul.gillard@gsk.com.
² GlaxoSmithKline, Avenue Fleming, 20, Wavre B1300, Belgium. Electronic address: Bernd.x.benninghoff@gsk.com.

PMID: 31072467
DOI: 10.1016/j.vaccine.2019.04.003

Comment

Response to: A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants

P Gillard et al. Vaccine. 2019.

. 2019 May 21;37(23):2990.

doi: 10.1016/j.vaccine.2019.04.003.

Authors

P Gillard¹, B Benninghoff²

Affiliations

¹ GlaxoSmithKline, Avenue Fleming, 20, Wavre B1300, Belgium. Electronic address: Paul.gillard@gsk.com.
² GlaxoSmithKline, Avenue Fleming, 20, Wavre B1300, Belgium. Electronic address: Bernd.x.benninghoff@gsk.com.

PMID: 31072467
DOI: 10.1016/j.vaccine.2019.04.003

No abstract available

PubMed Disclaimer

Comment in

Response to: Letter from P. Gillard and B. Benninghoff.
Rathi N, Desai S, Kawade A, Venkatramanan P, Kundu R, Lalwani SK, Dubey AP, Venkateswara Rao J, Narayanappa D, Ghildiyal R, Gogtay NJ, Venugopal P, Palkar S, Munshi R, Kang G, Babji S, Bavdekar A, Juvekar S, Ganguly N, Niyogi P, Uttam KG, Rajani HS, Kondekar A, Kumbhar D, Mohanlal S, Agarwal MC, Shetty P, Antony K, Gunale B, Dharmadhikari A, Tang Y, Kulkarni PS, Flores J. Rathi N, et al. Vaccine. 2019 May 21;37(23):2991-2992. doi: 10.1016/j.vaccine.2019.04.002. Vaccine. 2019. PMID: 31072468 No abstract available.

Comment on

A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants.
Rathi N, Desai S, Kawade A, Venkatramanan P, Kundu R, Lalwani SK, Dubey AP, Venkateswara Rao J, Narayanappa D, Ghildiyal R, Gogtay N, Venugopal P, Palkar S, Munshi R, Kang G, Babji S, Bavdekar A, Juvekar S, Ganguly N, Niyogi P, Ghosh Uttam K, Rajani HS, Kondekar A, Kumbhar D, Mohanlal S, Agarwal MC, Shetty P, Antony K, Gunale B, Dharmadhikari A, Tang Y, Kulkarni PS, Flores J. Rathi N, et al. Vaccine. 2018 Dec 18;36(52):7943-7949. doi: 10.1016/j.vaccine.2018.11.006. Epub 2018 Nov 9. Vaccine. 2018. PMID: 30420116 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Response to: A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants

Affiliations

Response to: A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants

Authors

Affiliations

Comment in

Comment on

Similar articles

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical